Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07226427 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 6 → 15 locationsv3
  2. Study sites: 1 to 6
    • Start date changed from estimate of Nov 2025 to Jan 10, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Trial Details
NCT Number NCT07226427
Lead Sponsor Stemline Therapeutics, Inc.
Conditions
(from sponsor)		 Platinum-resistant Ovarian Cancer
Related terms Ovarian Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov